Tang Gaoyan, Zhang Qianqian, Wang Fengxia, Zhang Hua, Qi Yuanling
Department of Oncology, Weifang People's Hospital (The First Affiliated Hospital of Shandong Second Medical University), Weifang, Shandong, 261041, People's Republic of China.
Onco Targets Ther. 2024 Aug 13;17:661-665. doi: 10.2147/OTT.S464678. eCollection 2024.
As one of the most common types of primary bone sarcomas in adolescents and young adults, osteosarcoma has a high probability of local invasion and distant metastasis with a poor prognosis.
Here, we report the case of a 34-year-old patient with advanced metastatic osteosarcoma. Considering the high expression of PD-L1 and the inability of the patient to tolerate chemotherapy, anti-PD-1 antibody (sintilimab 200 mg, q3w) and anti-angiogenesis drug (anlotinib 8 mg D1-14, q3w) were administered. The metastatic lesions were treated with local radiotherapy. The patient obtained an 11.7-month-sustained remission period, and he also enjoyed a better quality of life.
This case demonstrates that sintilimab plus anlotinib may be a feasible treatment regimen for osteosarcoma patients.
骨肉瘤是青少年和年轻成年人中最常见的原发性骨肉瘤类型之一，具有局部侵袭和远处转移的高可能性，预后较差。
在此，我们报告一例34岁晚期转移性骨肉瘤患者的病例。考虑到患者程序性死亡受体1配体（PD-L1）高表达且无法耐受化疗，给予抗程序性死亡受体1（PD-1）抗体（信迪利单抗200mg，每3周一次）和抗血管生成药物（安罗替尼8mg，第1 - 14天，每3周一次）治疗。对转移病灶进行了局部放疗。患者获得了11.7个月的持续缓解期，生活质量也有所改善。
该病例表明，信迪利单抗联合安罗替尼可能是骨肉瘤患者的一种可行治疗方案。
